CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress in a New Video Interview

CEL-SCI Corporation (NYSE MKT:CVM) announced today that a new video interview with Geert Kersten, Chief Executive Officer, is available for viewing. This new video summarizes CEL-SCI’s Phase 3 head and neck cancer trial progress and responds to questions about the ongoing $50 million plus arbitration that CEL-SCI brought against its former Clinical Research Organization (CRO). The arbitration hearing (“trial”) has been scheduled to start in spring of 2016.

The interview was conducted at the Source Capital 2016 Disruptive Growth & Healthcare Conference with Stock News Now and is available to view at https://www.youtube.com/watch?v=lQ8DnD6Uz3E or on CEL-SCI’s website at www.cel-sci.com/investor_relations.html.

This new video is different from last week’s video in which Mr. Kersten was a guest on Fox Business’ ‘Making Money with Charles Payne’. The segment, which focused on finding a cure to cancer, aired on Wednesday, February 17 between 6:00 and 7:00 p.m. ET. To view the segment, please visit: http://video.foxbusiness.com/v/4761247378001/are-scientists-on-the-cusp-of-finding-a-cure-for-cancer/?#sp=show-clips

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Almost 700 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160223005703/en/

CEL-SCI CorporationGavin de Windt, 703-506-9460